Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,7 +4,7 @@
4	4
5	5	= =
6	6
7		-Bausch Health Companies ([[BHC>>url:https://www.google.co.in/search?client=opera&hs=oYL&q=TSE:+BHC&stick=H4sIAAAAAAAAAONgecRozi3w8sc9YSm9SWtOXmPU4OIKzsgvd80rySypFJLiYoOyBKT4uHj00_UNM5LKKtKNC5J4FrFyhAS7Wik4eTgDAD7oLM5HAAAA&sa=X&ved=2ahUKEwjkooKnuIDnAhVTT30KHST3Br4QsRUwIXoECBcQAw]]) (formerly  Valeant Pharmaceuticals International, Inc.) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products.
	7	+Bausch Health Companies ([[BHC>>url:https://www.google.co.in/search?client=opera&hs=oYL&q=TSE:+BHC&stick=H4sIAAAAAAAAAONgecRozi3w8sc9YSm9SWtOXmPU4OIKzsgvd80rySypFJLiYoOyBKT4uHj00_UNM5LKKtKNC5J4FrFyhAS7Wik4eTgDAD7oLM5HAAAA&sa=X&ved=2ahUKEwjkooKnuIDnAhVTT30KHST3Br4QsRUwIXoECBcQAw]]) (formerly  Valeant Pharmaceuticals International, Inc.) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products.{{footnote}}https://www.bauschhealth.com{{/footnote}}
8	8
9	9	The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) sales in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products.
10	10
...	...	@@ -99,3 +99,5 @@
99	99	Our investment in R&D reflects our commitment to drive organic growth through internal development of new products, a pillar of our new strategy.
100	100
101	101	= References =
	102	+
	103	+{{putFootnotes/}}